Note to our followers: Our nearly 13-year run of daily publication of new content on HealthNewsReview.org came to a close at the end of 2018. Publisher Gary Schwitzer and other contributors may post new articles periodically. But all of the 6,000+ articles we have published contain lessons to help you improve your critical thinking about health care interventions. And those will be still be alive on the site for a couple of years.
8/6/2020

Crazy week of PR & news on studies should teach us how/what to ignore

On Tuesday, it was excitement over vaccine news in 12 monkeys. (Journalism example.) On Wednesday, it was excitement over vaccine news in cells from mice.  (National Institutes of Health PR example.) We’re going down the food chain.  Today is Thursday.  By Friday, we may be getting excited for nematodes that are vaccinated. Let me emphasize: […]

8/5/2020

Drug company influence on journalism

Many times through the years, HealthNewsReview.org has criticized the National Press Foundation in Washington, DC, for accepting drug company funding for journalism training.  (See articles from June 2009, July 2009, August 2010, September 2010, October 2010, March 2014, March 2015, December 2015, November 2019. I may have missed a few, but you get the picture.) They’re doing it […]

7/30/2020

Things you should think about when you hear “vaccine by end of the year”

On July 27, 2020, the Washington Post reported, Two coronavirus vaccines begin the last phase of testing: 30,000-person trials, wrapping it in historical terms: At 6:45 a.m. Monday, a volunteer in Savannah, Ga., received a shot in the arm and became the first participant in a massive human experiment that will test the effectiveness of an experimental […]

7/28/2020

What you need to know about the Alzheimer’s test news

For years, substances called tau protein or beta-amyloid have been theorized to be signs or causes of Alzheimer’s disease.  There have been many reports of tests and treatments based on theories that tau and/or amyloid are at least signs, if not causes, of Alzheimer’s. Scientific uncertainty remains about the precise role of tau and amyloid […]

7/24/2020

HealthNewsReview.org in the news about COVID-19

I’ve been asked to do more interviews in the past six months than in any recent comparable time span.  COVID-19 is almost always the reason for the requests. Some of the more recent requests were spawned by the JAMA Viewpoint article, Communicating Science in the Time of a Pandemic, that I co-authored with Richard Saitz, MD, […]

7/21/2020

One day of COVID-19 drug & vaccine news provides cautious reminders

Before I even turned on my computer yesterday, the BBC had blared this headline about a trial of the protein interferon beta:The sub-headline read: The preliminary results of a clinical trial suggest a new treatment for Covid-19 reduces the number of patients needing intensive care, according to the UK company that developed it. Eventually some […]

7/21/2020

JAMA: Communicating Science in the Time of a Pandemic

Dr. Richard Saitz of Boston University School of Public Health and I co-authored this piece in the Journal of the American Medical Association.  Here is an excerpt:

7/17/2020

Criticism of NY Times’ Coronavirus Drug and Treatment Tracker

Yesterday on Twitter, several clinician-researchers urged me to weigh in on the New York Times’ introduction of a new Coronavirus Drug and Treatment Tracker. They were troubled by it. I was, too, when I saw it. But I had no time to address it yesterday and – more than 24 hours later – I still […]

7/13/2020

Why make international news out of 9 vague patient reports on remdesivir?

The Reuters headline blared, “One in three South Korean COVID-19 patients improve with remdesivir.”  The first sentence of the story repeated that number: “One in three South Korean patients seriously ill with COVID-19 showed an improvement in their condition after being given Gilead Sciences Inc’s antiviral remdesivir, health authorities said.” One in three.  Was that 1,000 […]

7/3/2020

Some global reaction to the news of US mass purchase of remdesivir

Canadian physician-researcher James Brophy of McGill University read the news announcing, “US buys up world stock of key Covid-19 drug remdesivir.” Rather than reacting with shock and scorn as many observers did, Brophy celebrated the announcement as “good news for the rest of us” around the globe. Why? He explained in an opinion piece published […]

Toolkit

Tips & Resources for Analyzing Health Care Claims

View More

Toolkit